Medicina basada en la evidencia y la lectura crítica en hepatología
DOI:
https://doi.org/10.52784/27112330.116Palabras clave:
medicina basada en la evidencia, lectura crítica, revisiones sistemáticas, guías de práctica clínica, carcinoma hepatocelular.Resumen
La medicina basada en la evidencia se fundamenta en la integración de la situación clínica del paciente, la experiencia del profesional o equipo a cargo, y la utilización de la mejor evidencia científica disponible, apoyada en la lectura crítica como pilar fundamental. Desde sus inicios, mucho se ha expuesto de sus ventajas, sus falencias y de cómo se adapta a la práctica clínica. Su implementación también ha hecho evidente la brecha que existe en la apreciación de artículos médicos y la interpretación de los resultados. Esta revisión narrativa busca exponer algunas consideraciones de la medicina basada en la evidencia y la importancia de la lectura crítica en el campo de la hepatología, y su utilidad en contexto del carcinoma hepatocelular.
Descargas
Referencias bibliográficas
Sanderlin BW, AbdulRahim N. Evidence-based medicine, part 6. An introduction to critical appraisal of clinical practice guidelines. J Am Osteopat Assoc. 2007;107:321-324.
Garba S. Proliferations of scientific medical journals: A burden or a blessing. Oman Med J. 2010;25:311-314. https://doi.org/10.5001/omj.2010.100.
Alper BS, Hand JA, Elliott SG, Kinkade S, Hauan MJ, Onion DK, et al. How much effort is needed to keep up with the literature relevant for primary care? J Med Libr Assoc. 2004;92:429-437.
Silva-Numa S. Colombia se une a la medicina basada en evidencia. El Espectador 2019, 17 de marzo; Salud. Disponible en: https://www.elespectador.com/noticias/salud/colombia-se-une-la-medicina-basada-en-evidencia-articulo-845443.
Dickersin K, Straus SE, Bero LA. Evidence based medicine: increasing, not dictating, choice. BMJ 2007;334:s10. https://doi.org/10.1136/bmj.39062.639444.94.
Cornberg M, Tacke F, Karlsen TH. Clinical Practice Guidelines of the European Association for the study of the Liver-Advancing methodology but preserving practicability. J Hepatol 2019;70:5-7. https://doi.org/10.1016/j.jhep.2018.10.011.
Younossi Z, Guyatt G. Evidence-based medicine: a method for solving clinical problems in hepatology. Hepatology. 1999;30:829-32. https://doi.org/10.1002/hep.510300408.
Ashcroft R, ter Meulen R. Ethics, philosophy, and evidence based medicine. J Med Ethics. 2004;30:119. https://doi.org/10.1136/jme.2003.007286.
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72. https://doi.org/10.1136/bmj.312.7023.71.
Young JM, Solomon MJ. How to critically appraise an article. Nat Clin Pract Gastroenterol Hepatol 2009;6:82-91. https://doi.org/10.1038/ncpgasthep1331
Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature 2019;567:305-307. https://doi.org/10.1038/d41586-019-00857-9.
Jiménez-Villa J, Argimón-Pallàs J. Medicina basada en la evidencia en Atención Primaria. In: Martín-Zurro A, Cano Pérez JF, Gené Badia J, eds. Atención primaria. Principios, organización y métodos en medicina de familia. 8th ed. Barcelona: Elsevier; 2019. p. 228-246.
Málaga G, Neira-Sánchez ER. La medicina basada en la evidencia, su evolución a 25 años desde su diseminación, promoviendo una práctica clínica científica, cuidadosa, afectuosa y humana. Acta Med Peru 2018;35:121-126.
Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. BMJ Evid Based Med 2002;7:36-38. https://doi.org/10.1136/ebm.7.2.36.
AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 update: AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-1492. https://doi.org/10.1093/cid/ciy585.
Manterola C, Asenjo-Lobos C, Otzen T. [Hierarchy of evidence: Levels of evidence and grades of recommendation from current use]. Rev Chilena Infectol 2014;31:705-718. https://doi.org/10.4067/S0716-10182014000600011.
Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evidence-based medicine 2016;21:125-127. https://doi.org/10.1136/ebmed-2016-110401.
Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017;66:1047-1081. https://doi.org/10.1016/j.jhep.2016.12.003.
Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-1316. https://doi.org/10.1016/j.jclinepi.2011.06.004.
Walach H, Falkenberg T, Fønnebø V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006 June 24;6:29. https://doi.org/10.1186/1471-2288-6-29.
Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid hierarchy?. Circulation 2008;118:1675-1684. https://doi.org/10.1161/CIRCULATIONAHA.107.721357.
Tugwell P, Knottnerus JA. Is the ‘Evidence-Pyramid’now dead?. Journal Clin Epidemiol 2015;68:1247-1250. https://doi.org/10.1016/j.jclinepi.2015.10.001.
Leng G, Harrow E. Library & Resources/International Guideline Library. Perthshire, Scotland: Guidelines International Network; 2019. Acceso 13 de enero de 2017. Disponible en https://g-i-n.net/.
Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD Clinical Practice Guidelines: A critical review of scientific evidence and evolving recommendations. Hepatology 2013;58:2142-2152. https://doi.org/10.1002/hep.26578.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-386. https://doi.org/10.1002/ijc.29210.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;78:723-750. https://doi.org/10.1002/hep.29913.
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370. https://doi.org/10.1007/s12072-017-9799-9.
Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance: Practice guidelines and real-life practice. J Clin Gastroenterol 2016 Feb;50:120-133. https://doi.org/10.1097/MCG.0000000000000446.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022. https://doi.org/10.1002/hep.24199.
Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso M del C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67. https://doi.org/10.1002/hep.510290145.
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422. https://doi.org/10.1007/s00432-004-0552-0.
Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist 2010;15:34-41. https://doi.org/10.1634/theoncologist.2010-S4-34.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2.
Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, et al. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-995. https://doi.org/10.1007/s12094-015-1451-3.
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380. https://doi.org/10.1002/hep.29086.
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:238-255. https://doi.org/10.1093/annonc/mdy308.
Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41. https://doi.org/10.1080/13651820410024058.
Guarino M, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone-Megna A, et al. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. J Gastroenterol Hepatol 2018;33:1123-1130. https://doi.org/10.1111/jgh.14013.
Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis 2014;46:549-555. https://doi.org/10.1016/j.dld.2014.02.012.
Guyatt G, Cook D, Haynes B. Evidence based medicine has come a long way. BMJ 2004;329:990-991. https://doi.org/10.1136/bmj.329.7473.990.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
